- AstraZeneca has licensed Vanderbilt University’s coronavirus-neutralizing Abs & plans to advance a pair of these mAbs into clinical development as a combination therapy for COVID-19. The agreement follows AstraZeneca and Vanderbilt collaboration in Apr’20
- AstraZeneca has evaluated the ability of 1,500+ mAbs to bind to the SARS-CoV-2 virus and inhibit its capacity to infect healthy cells in a laboratory setting. Based on pre-clinical results, the company has signed an exclusive license to six Abs currently in Vanderbilt’s portfolio targeting COVID-19. 2 out of 6 mAbs will progress into clinical evaluation as a combination approach within the next 2mos.
- Additionally, AstraZeneca has signed an interagency agreement with DARPA and BARDA to support the development of mAb against COVID-19 including P-I clinical study and the manufacturing of the investigational product for testing in P-I
Click here to read full press release/ article | Ref: AstraZeneca | Image: AstraZeneca